Skip to content Skip to navigation

Executive Summary

CCRM is a not-for-profit, public-private consortium supporting the development of foundational technologies that accelerate the commercialization of cell and gene therapies, and regenerative medicine technologies.

Unmet Need 
Cell and gene therapies, and regenerative medicine-based products and therapies have the potential to transform health care, with the promise to treat, manage and perhaps cure some of the most debilitating and costly diseases in the world today. However, many new potentially life-changing cell, gene and regenerative medicine-based treatments never reach patients because they are not successfully moved from the laboratory to the clinic.

Canadian scientific excellence in stem cells, bioengineering and biomaterials combined with existing infrastructure positions CCRM to coordinate product development and commercialization in a capital-efficient manner.

Business Strategy

  • ENABLE unique translational platforms that address the key bottlenecks in cell, gene and regenerative medicine commercialization
  • INTEGRATE Canada’s strength in stem cell and bioengineering with dynamic business leadership
  • ENGAGE industry partners, making CCRM a global nexus of regenerative medicine commercialization

From Concept to Market

  • BUILD: business, regulatory and IP team with commercialization and technology expertise
  • ADVANCE: cell reprogramming and engineering, technology translation, and protocol development
  • BridGE: pre-clinical to commercially ready cell and gene therapy process optimization and scale-up
  • DELIVER: GMP cell and gene therapy manufacturing, coming in 2019
  • LAUNCH: your business

Value Proposition

  • Network of business and scientific leaders
  • Product development team to augment academic expertise and facilities
  • Industry consortium that reconciles technology push with market pull

Reasons to Work with CCRM

  • For Industry: access to state-of-the-art discoveries, facilities and expertise
  • For Academics: business leaders and corporate partners to accelerate commercialization
  • For Investors: risk-mitigated and capital-efficient product development

Our team combines extensive experience in company creation, academic excellence and seasoned professionals sourced from industry. Members of CCRM’s Strategic Advisory Board are shared with the Ontario Institute for Regenerative Medicine and represent international scientific excellence in stem cell biology and regenerative medicine.

Download the 2017 Executive Summary PDF version here.